




RealRate

PHARMACEUTICAL 2022

Neubase Therapeutics Inc
Rank 166 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Neubase Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Neubase Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 78% points. The greatest weakness of Neubase Therapeutics Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 12% points.

The company's Economic Capital Ratio, given in the ranking table, is 335%, being 60% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	54,929
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,194
Liabilities, Non-Current	5,794
Other Assets	6,775
Other Compr. Net Income	0
Other Expenses	2,888
Other Liabilities	110
Other Net Income	1,156
Other Revenues	0
Property and Equipment	2,464
Research and Development	11,475
Selling, General and Administrative Expense	12,202

Output Variable	Value in 1000 USD
Assets	64,168
Liabilities	10,098
Expenses	26,565
Revenues	0
Stockholders Equity	54,070
Net Income	-25,409
Comprehensive Net Income	-25,409
BaseVar	50,994
ECR before LimitedLiability	249%
Economic Capital Ratio	335%